Recurrent or progressive primary malignant brain tumors are among the malignancies with a poor prognosis. They refer to primary brain tumors that either recur after standard treatment or show disease progression during the course of standard therapy. This group includes a variety of histological types, most commonly glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and primary central nervous system lymphoma.
Tumor tissue specimens must be CD70-positive as determined by immunohistochemistry (IHC).
Patients with brainstem recurrence, spinal dissemination, or extracranial metastasis.
Single group
CHT 101
Biological/VaccineCHT101 is an allogeneic CD70-targeted chimeric antigen receptor Tcell therapy, intended to be administered locally for the treatment of primary malignant brain tumors.
Safety and Tolerability
Treatment-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events
Objective response rate (ORR)
Progress-free survival(PFS)
PFS will be assessed from CHT 101 infusion to death from any cause or the first assessment of progression
Overall survival (OS )
OS will be assessed from CHT 101 infusion to death
pharmacokinetics (PK)
Concentration levels of CHT 101
Click on the lead sponsor to view all of their trials.
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Nanjing Miracle Biotech Co. Ltd.
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
